Products from BPS Bioscience require a minimum order value above 400€
Application: Useful for binding assays.
Assay Conditions: This protein was tested by ELISA for its ability to bind to KLK2.
Background: Kallikrein-2 (KLK2) is a trypsin-like serine protease. This protein is a member of the glandular kallikrein family and is critical in the enzymatic process as it selectively cleaves the Met-Lys and Arg-Ser bonds in kininogen, thereby releasing Lys-bradykinin . This proteolytic activity contributes to the production of bradykinin, a bioactive peptide with multiple roles in regulating blood pressure, inflammation, and vascular permeability. It is expressed by prostate epithelial cells and it is regulated by androgen receptor signal. Its expression in prostate adenocarcinoma is nearly ubiquitous in the localized and castrate-sensitive settings, and high expression levels are maintained in metastatic castration-resistant PC (mCRPC). Its pattern of expression makes an ideal target in the treatment of mCRPC. Pasritamig is a human bispecific antibody that simultaneously binds to CD3 on T cells and cell surface KLK2 on tumor cells, enhancing the cytotoxicity towards KLK2-expressing tumor cells and it is currently under clinical trial.
Description: Pasritamig is a KLK2 (kallikrein-2)/CD3E-targeting (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type bispecific antibody. Figure 1: Schematic representation of Pasritamig.
Format: Aqueous buffer solution.
Formulation: Supplied as a 0.22 μm filtered solution in 100 mM Pro-Ac, 20 mM Arg, pH 5.0.
Reconstitution: The product can be reconstituted/diluted with sterile PBS or saline.
Storage Stability: Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoidmultiple freeze-thaws.
Target: CD3, IL-13
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
